Panacea Biotec is presently trading at Rs. 202.00, up with the aid of 20.85 factors or 11.51% from its preceding final of Rs. 181.15 on the BSE.

The scrip opened at Rs. 202.15 and has touched a high and low of Rs. 212.Eighty five and Rs. 2 hundred.15 respectively. So a long way 141170 shares had been traded at the counter.

The BSE organization ‘B’ stock of face price Rs. 1 has touched a 52 week excessive of Rs. 313.50 on 10-Apr-2018 and a fifty two week low of Rs. 138.20 on 06-Dec-2018.

Last one week excessive and occasional of the scrip stood at Rs. 214.50 and Rs. 179.20 respectively. The cutting-edge market cap of the company is Rs. 1247.07 crore.

The promoters preserving inside the organisation stood at seventy three.59%, at the same time as Institutions and Non-Institutions held 1.Forty six% and 24.Ninety four% respectively.

India Resurgence Fund (IndiaRF), promoted by way of Piramal Enterprises and Bain Capital Credit, along side its affiliates to invest upto Rs 992 crore in Panacea Biotec. The funding proceeds will be used for a one-time settlement with current creditors, preferred working capital and boom requirements of the Company.

This investment is dependent through manner of Non-Convertible Debentures (NCDs) of as much as Rs 864 crore and subscription quantity of Rs 32 crore in the direction of share warrants to be allocated on a preferential foundation. The subscription amount represents 25% of overall amount of Rs 128 crore proposed to be raised upon issuance of equity shares against warrants. Subject to workout of warrants, IndiaRF (at the side of its associates) will collectively come to be proudly owning 10.4% stake within the employer on a fully diluted foundation.